VTVT
vTv Therapeutics Inc.
Biotechnology
Market Cap$261M
5Y Perf.-56.2%
Compare Stocks
2 / 10Try these comparisons:
Stock Comparison
VTVT vs ATHA
Revenue, margins, valuation, and 5-year total return — side by side.
ATHA
Athira Pharma, Inc.
Biotechnology
Market Cap$17M
5Y Perf.-97.4%
VTVT vs ATHA — Key Financials
Market cap, revenue, margins, and valuation side-by-side.
| Company Snapshot | VTVT | ATHA |
|---|---|---|
| Industry | Biotechnology | Biotechnology |
| Market Cap | $261M | $17M |
| Revenue (TTM) | $-24K | $0.00 |
| Net Income (TTM) | $-27M | $-129M |
| Total Debt | $0.00 | $803K |
| Cash & Equiv. | $89M | $69M |
VTVT vs ATHA — Long-Term Stock Performance
Price return indexed to 100 at period start. Dividends excluded.
VTVT
ATHA
| Stock | Sep 20 | May 26 | Return |
|---|---|---|---|
| vTv Therapeutics In… (VTVT) | 100 | 43.8 | -56.2% |
| Athira Pharma, Inc. (ATHA) | 100 | 2.6 | -97.4% |
Price return only. Dividends and distributions are not included.
Quick Verdict: VTVT vs ATHA
Each card shows where this stock fits in a portfolio — not just who wins on paper.
Bottom line: VTVT and ATHA are tied at the top with 2 categories each — the right choice depends on your priorities. Athira Pharma, Inc. is the stronger pick specifically for growth and revenue expansion and recent price momentum and sentiment. As sector peers, any of these can serve as alternatives in the same allocation.
VTVT
vTv Therapeutics Inc.
The Income Pick
VTVT has the current edge in this matchup, primarily because of its strength in income & stability and long-term compounding.
- beta 0.81
- -87.0% 10Y total return vs ATHA's -97.5%
- Lower volatility, beta 0.81, current ratio 13.54x
Best for: income & stability and long-term compounding
ATHA
Athira Pharma, Inc.
The Growth Play
ATHA is the clearest fit if your priority is growth exposure.
- EPS growth 2.0%
- -64.6% revenue growth vs VTVT's -100.0%
- +81.6% vs VTVT's +52.5%
Best for: growth exposure
See the full category breakdown
| Category | Winner | Why |
|---|---|---|
| Growth | ATHA | -64.6% revenue growth vs VTVT's -100.0% |
| Stability / Safety | VTVT | Beta 0.81 vs ATHA's 1.47 |
| Dividends | Tie | Neither stock pays a meaningful dividend |
| Momentum (1Y) | ATHA | +81.6% vs VTVT's +52.5% |
| Efficiency (ROA) | VTVT | -43.5% ROA vs ATHA's -225.7% |
VTVT vs ATHA — Revenue Breakdown by Segment
How each company's revenue is distributed across its business units
FY 2024
Segment breakdown not available.
VTVT vs ATHA — Financial Metrics
Side-by-side numbers across 2 stocks — who leads on profitability, valuation, growth, and risk.
BEST OVERALLVTVTLAGGINGATHA
ATHAAthira Pharma, Inc.
1leads
VTVTvTv Therapeutics Inc.
3leads
6 Total Categories
CATEGORYLEADERvs ATHAMETRICS WON
Income & Cash FlowRevenue, margins, and cash flow strength
ATHA1/1
Valuation MetricsMultiples, price ratios, and targets
Tied
—
Profitability & EfficiencyROE, ROIC, leverage, and quality scores
VTVT6/6
Total Returns1Y, 3Y, 5Y total returns with dividends
VTVT5/6
Risk & VolatilityBeta, volatility, and downside exposure
VTVT2/2
Analyst OutlookRatings, price targets, and dividends
—
—
Income & Cash Flow (Last 12 Months)
ATHA leads this category, winning 1 of 1 comparable metric.
Income & Cash Flow (Last 12 Months)
ATHA and VTVT operate at a comparable scale, with $0 and -$24,000 in trailing revenue.
| Metric | VTVTvTv Therapeutics … | ATHAAthira Pharma, In… |
|---|---|---|
| RevenueTrailing 12 months | -$24,000 | $0 |
| EBITDAEarnings before interest/tax | -$33M | -$110M |
| Net IncomeAfter-tax profit | -$27M | -$129M |
| Free Cash FlowCash after capex | -$25M | -$52M |
| Gross MarginGross profit ÷ Revenue | — | — |
| Operating MarginEBIT ÷ Revenue | — | — |
| Net MarginNet income ÷ Revenue | — | — |
| FCF MarginFCF ÷ Revenue | — | — |
| Rev. Growth (YoY)Latest quarter vs prior year | -2.4% | — |
| EPS Growth (YoY)Latest quarter vs prior year | +7.9% | +24.8% |
ATHA leads this category, winning 1 of 1 comparable metric.
Valuation Metrics
Evenly matched — VTVT and ATHA each lead in 1 of 2 comparable metrics.
Valuation Metrics
| Metric | VTVTvTv Therapeutics … | ATHAAthira Pharma, In… |
|---|---|---|
| Market CapShares × price | $261M | $17M |
| Enterprise ValueMkt cap + debt − cash | $173M | -$30M |
| Trailing P/EPrice ÷ TTM EPS | -9.70x | -0.17x |
| Forward P/EPrice ÷ next-FY EPS est. | — | — |
| PEG RatioP/E ÷ EPS growth rate | — | — |
| EV / EBITDAEnterprise value multiple | — | — |
| Price / SalesMarket cap ÷ Revenue | — | — |
| Price / BookPrice ÷ Book value/share | 4.06x | 0.37x |
| Price / FCFMarket cap ÷ FCF | — | — |
Evenly matched — VTVT and ATHA each lead in 1 of 2 comparable metrics.
Profitability & Efficiency
VTVT leads this category, winning 6 of 6 comparable metrics.
Profitability & Efficiency
VTVT delivers a -73.8% return on equity — every $100 of shareholder capital generates $-74 in annual profit, vs $-4 for ATHA. On the Piotroski fundamental quality scale (0–9), VTVT scores 3/9 vs ATHA's 2/9, reflecting mixed financial health.
| Metric | VTVTvTv Therapeutics … | ATHAAthira Pharma, In… |
|---|---|---|
| ROE (TTM)Return on equity | -73.8% | -3.8% |
| ROA (TTM)Return on assets | -43.5% | -2.3% |
| ROICReturn on invested capital | — | — |
| ROCEReturn on capital employed | -56.4% | -2.3% |
| Piotroski ScoreFundamental quality 0–9 | 3 | 2 |
| Debt / EquityFinancial leverage | — | 0.03x |
| Net DebtTotal debt minus cash | -$89M | -$68M |
| Cash & Equiv.Liquid assets | $89M | $69M |
| Total DebtShort + long-term debt | $0 | $803,000 |
| Interest CoverageEBIT ÷ Interest expense | -5408.17x | — |
VTVT leads this category, winning 6 of 6 comparable metrics.
Total Returns (Dividends Reinvested)
VTVT leads this category, winning 5 of 6 comparable metrics.
Total Returns (Dividends Reinvested)
A $10,000 investment in VTVT five years ago would be worth $3,142 today (with dividends reinvested), compared to $235 for ATHA. Over the past 12 months, ATHA leads with a +81.6% total return vs VTVT's +52.5%. The 3-year compound annual growth rate (CAGR) favors VTVT at -0.2% vs ATHA's -46.7% — a key indicator of consistent wealth creation.
| Metric | VTVTvTv Therapeutics … | ATHAAthira Pharma, In… |
|---|---|---|
| YTD ReturnYear-to-date | -21.6% | -37.6% |
| 1-Year ReturnPast 12 months | +52.5% | +81.6% |
| 3-Year ReturnCumulative with dividends | -0.5% | -84.8% |
| 5-Year ReturnCumulative with dividends | -68.6% | -97.7% |
| 10-Year ReturnCumulative with dividends | -87.0% | -97.5% |
| CAGR (3Y)Annualised 3-year return | -0.2% | -46.7% |
VTVT leads this category, winning 5 of 6 comparable metrics.
Risk & Volatility
VTVT leads this category, winning 2 of 2 comparable metrics.
Risk & Volatility
VTVT is the less volatile stock with a 0.81 beta — it tends to amplify market swings less than ATHA's 1.47 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. VTVT currently trades 70.5% from its 52-week high vs ATHA's 51.9% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | VTVTvTv Therapeutics … | ATHAAthira Pharma, In… |
|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 0.81x | 1.47x |
| 52-Week HighHighest price in past year | $44.00 | $8.36 |
| 52-Week LowLowest price in past year | $14.00 | $2.30 |
| % of 52W HighCurrent price vs 52-week peak | +70.5% | +51.9% |
| RSI (14)Momentum oscillator 0–100 | 41.1 | 38.4 |
| Avg Volume (50D)Average daily shares traded | 61K | 46K |
VTVT leads this category, winning 2 of 2 comparable metrics.
Analyst Outlook
Insufficient data to determine a leader in this category.
Analyst Outlook
| Metric | VTVTvTv Therapeutics … | ATHAAthira Pharma, In… |
|---|---|---|
| Analyst RatingConsensus buy/hold/sell | Buy | — |
| Price TargetConsensus 12-month target | $51.33 | — |
| # AnalystsCovering analysts | 14 | — |
| Dividend YieldAnnual dividend ÷ price | — | — |
| Dividend StreakConsecutive years of raises | — | — |
| Dividend / ShareAnnual DPS | — | — |
| Buyback YieldShare repurchases ÷ mkt cap | 0.0% | 0.0% |
Insufficient data to determine a leader in this category.
Key Takeaway
VTVT leads in 3 of 6 categories (Profitability & Efficiency, Total Returns). ATHA leads in 1 (Income & Cash Flow). 1 tied.
Best OverallvTv Therapeutics Inc. (VTVT)Leads 3 of 6 categories
Loading custom metrics...
VTVT vs ATHA: Frequently Asked Questions
8 questions · data-driven answers · updated daily
01Is VTVT or ATHA a better buy right now?
Analysts rate vTv Therapeutics Inc.
(VTVT) a "Buy" — based on 14 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.
02Which is the better long-term investment — VTVT or ATHA?
Over the past 5 years, vTv Therapeutics Inc.
(VTVT) delivered a total return of -68. 6%, compared to -97. 7% for Athira Pharma, Inc. (ATHA). Over 10 years, the gap is even starker: VTVT returned -87. 0% versus ATHA's -97. 5%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
03Which is safer — VTVT or ATHA?
By beta (market sensitivity over 5 years), vTv Therapeutics Inc.
(VTVT) is the lower-risk stock at 0. 81β versus Athira Pharma, Inc. 's 1. 47β — meaning ATHA is approximately 82% more volatile than VTVT relative to the S&P 500.
04Which is growing faster — VTVT or ATHA?
On earnings-per-share growth, the picture is similar: Athira Pharma, Inc.
grew EPS 2. 0% year-over-year, compared to 0. 0% for vTv Therapeutics Inc.. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.
05Which has better profit margins — VTVT or ATHA?
vTv Therapeutics Inc.
(VTVT) is the more profitable company, earning 0. 0% net margin versus 0. 0% for Athira Pharma, Inc. — meaning it keeps 0. 0% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: VTVT leads at 0. 0% versus 0. 0% for ATHA. At the gross margin level — before operating expenses — VTVT leads at 0. 0%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
06Which pays a better dividend — VTVT or ATHA?
None of the stocks in this comparison currently pay a material dividend.
All are effectively zero-yield and should be held for capital appreciation rather than income.
07Is VTVT or ATHA better for a retirement portfolio?
For long-horizon retirement investors, vTv Therapeutics Inc.
(VTVT) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0. 81)). Both have compounded well over 10 years (VTVT: -87. 0%, ATHA: -97. 5%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
08What are the main differences between VTVT and ATHA?
Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.
These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
Find Stocks Like These
Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform both.
You Might Also Compare
Based on how these companies actually compete and overlap — not just which sector they're filed under.